Company news
Jazz Pharmaceuticals plc news in 2023
Jazz Pharmaceuticals plc's news releases, calls and decks from 2023, newest first.
Jazz Pharmaceuticals Provides Update on Phase 2 Trial of Investigational JZP150 in Adult Patients with Post-Traumatic Stress Disorder
December 20, 2023
Jazz Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
December 19, 2023
Jazz Pharmaceuticals Presents Updated Phase 2a Data at SABCS 2023 Showcasing Potential of Zanidatamab in HER2+/HR+ Metastatic Breast Cancer
December 7, 2023
Jazz Pharmaceuticals to Present Long-Term and Real-World Data Emphasizing Commitment to Treatment-Resistant Epilepsy at the 2023 American Epilepsy Society Annual Meeting
November 30, 2023
Jazz Pharmaceuticals to Present New Data Highlighting Advancements in Solid Tumors and Rare Blood Cancers at Upcoming Oncology Meetings
November 29, 2023
Jazz Pharmaceuticals Announces Third Quarter 2023 Financial Results and Updates Financial Guidance
November 7, 2023
Jazz Pharmaceuticals and MD Anderson Announce Five-Year Collaboration to Evaluate Zanidatamab in HER2-Expressing Cancers
November 6, 2023
Jazz Pharmaceuticals to Participate in Upcoming November Investor Conferences
October 31, 2023
Jazz Pharmaceuticals to Report 2023 Third Quarter Financial Results on November 8, 2023
October 24, 2023
Jazz Pharmaceuticals Presents Data Highlighting the Continued Need for Low-Sodium Treatment Option Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution and Real-World, Evidence-Based Approaches for Individualized Treatment in Adul...
October 22, 2023
Jazz Pharmaceuticals to Present Latest Advancements in Sleep Medicine at World Sleep 2023
October 17, 2023
Jazz Pharmaceuticals to Showcase Growing Impact in Solid Tumor Oncology Research at ESMO 2023
October 15, 2023
Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
September 20, 2023
Jazz Pharmaceuticals to Participate in Three Upcoming Investor Conferences
September 12, 2023
Jazz Pharmaceuticals Announces Key Update to Leadership Team
September 11, 2023
Jazz Pharmaceuticals Showcases Impact of Sleep Medicine Portfolio at Psych Congress 2023
September 10, 2023
Jazz Pharmaceuticals to Participate in Citi's 18th Annual BioPharma Conference
August 23, 2023
Jazz Pharmaceuticals Announces Second Quarter 2023 Financial Results and Raises 2023 Full Year Financial Guidance
August 8, 2023
Jazz Pharmaceuticals to Report 2023 Second Quarter Financial Results on August 9, 2023
July 25, 2023
Jazz Pharmaceuticals Receives CHMP Positive Opinion for JZP458 (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
July 20, 2023
Jazz Pharmaceuticals and Zymeworks Present Positive Pivotal Phase 2b Trial Data at ASCO 2023 Evaluating Zanidatamab in HER2-Amplified Biliary Tract Cancers
June 1, 2023
Jazz Pharmaceuticals Demonstrates Continued Leadership in Sleep Medicine with New Data Presentations at SLEEP 2023
May 30, 2023
Jazz Pharmaceuticals to Participate in the 2023 Goldman Sachs Global Healthcare Conference
May 29, 2023
Jazz Pharmaceuticals to Host Zanidatamab KOL Investor Webcast on June 2, 2023
May 24, 2023
Jazz Pharmaceuticals Announces First Quarter 2023 Financial Results and Affirms 2023 Financial Guidance
May 9, 2023
Jazz Pharmaceuticals to Participate in the 2023 RBC Capital Markets Global Healthcare Conference
May 1, 2023
Jazz Pharmaceuticals to Showcase Rapidly Expanding Oncology Pipeline and Advances in Current Product Portfolio at ASCO 2023
April 26, 2023
Jazz Pharmaceuticals to Report 2023 First Quarter Financial Results on May 10, 2023
April 25, 2023
Jazz Pharmaceuticals to Present Advancements in Neuroscience at American Academy of Neurology Annual Meeting
April 18, 2023
Jazz Pharmaceuticals Expands Support of the American Heart Association to Raise Awareness of the Link Between Sleep Disorders and Heart Health
March 29, 2023
Jazz Pharmaceuticals to Present Data at 2023 AACR Annual Meeting Showcasing New Zepzelca® (lurbinectedin) Data and Expanded Oncology Pre-Clinical and Clinical Pipeline
March 14, 2023
Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2022 Financial Results and Provides 2023 Financial Guidance
February 28, 2023
Jazz Pharmaceuticals to Report 2022 Fourth Quarter and Full Year Financial Results on March 1, 2023
February 14, 2023
Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phase 2 Trial Evaluating Zanidatamab in HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma
January 18, 2023
Jazz Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 2, 2023
Calls in 2023
Decks in 2023
- 41st Annual J.P. Morgan Healthcare Conference (January 2023)
Conference · 36 slides · Jan 9, 2023